Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib plus Palbociclib in KRAS-mutated Solid Tumors
NCT06947811Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib and palbociclib in solid tumor, sponsored by Sun Yat-sen University. Primary endpoints: Number of Participants With Treatment-related Adverse Events at 50 months and Objective Response Rate at 42 months. Started Jun 2025; status: recruiting.
02
Drugs
almonertinibpalbociclib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06947811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947811.